Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 2405291, 13 pages
https://doi.org/10.1155/2017/2405291
Research Article

Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis

1Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
2Institute of Clinical Pharmacology, Beijing An Zhen Hospital, Capital Medical University, Beijing 100029, China
3Department of Dermatology, China-Japan Friendship Hospital, Beijing 100029, China
4Department of Dermatology, Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China
5Department of Dermatology and Venerology, Peking University First Hospital, Beijing 100034, China
6Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
7Molecular Medicine Laboratory and Chieng Genomics Center, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
8Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong
9E-Institute of Chinese Traditional Internal Medicine, Shanghai Municipal Education Commission, Shanghai 201203, China
10Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing 100029, China

Correspondence should be addressed to Youwen Zhou; ac.cbu@uohz.newuoy, Aiping Lu; kh.ude.ubkh@ulgnipia, and Cheng Xiao; moc.621@2182002cx

Received 11 October 2016; Accepted 30 November 2016; Published 25 January 2017

Academic Editor: Qingdong Guan

Copyright © 2017 Yong Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. N. Mehta, Y. Yu, R. Pinnelas et al., “Attributable risk estimate of severe psoriasis on major cardiovascular events,” American Journal of Medicine, vol. 124, no. 8, pp. 775.e1–775.e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. H. Solomon, N. J. Goodson, J. N. Katz et al., “Patterns of cardiovascular risk in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 12, pp. 1608–1612, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. B. Kimball, J. Schenfeld, N. A. Accortt, M. S. Anthony, K. J. Rothman, and D. Pariser, “Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005–09,” British Journal of Dermatology, vol. 170, no. 2, pp. 366–373, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Mellemkjær, M. S. Linet, G. Gridley, M. Frisch, H. Møller, and J. H. Olsen, “Rheumatoid arthritis and cancer risk,” European Journal of Cancer, vol. 32, no. 10, pp. 1753–1757, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Ganzetti, A. Campanati, E. Molinelli, and A. Offidani, “Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background,” World Journal of Cardiology, vol. 8, no. 2, pp. 120–131, 2016. View at Publisher · View at Google Scholar
  6. E. M. Ruderiman, J. M. Crawford, A. Maier, J. J. Liu, E. M. Gravallese, and M. E. Weinblatt, “Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis,” British Journal of Rheumatology, vol. 36, no. 2, pp. 210–213, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kagami, H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt, “Circulating Th17, Th22, and Th1 cells are increased in psoriasis,” Journal of Investigative Dermatology, vol. 130, no. 5, pp. 1373–1383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Oka, T. Mabuchi, A. Ozawa, and H. Inoko, “Current understanding of human genetics and genetic analysis of psoriasis,” Journal of Dermatology, vol. 39, no. 3, pp. 231–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Michalak-Stoma, A. Pietrzak, J. C. Szepietowski, A. Zalewska-Janowska, T. Paszkowski, and G. Chodorowska, “Cytokine network in psoriasis revisited,” European Cytokine Network, vol. 22, no. 4, pp. 160–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Choy, “Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis,” Rheumatology (Oxford), vol. 51, supplement 5, pp. v3–v11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. E. R. Mardis, “The impact of next-generation sequencing technology on genetics,” Trends in Genetics, vol. 24, no. 3, pp. 133–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. V. H. Teixeira, R. Olaso, M.-L. Martin-Magniette et al., “Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients,” PLOS ONE, vol. 4, Article ID e6803, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Li, L. C. Tsoi, W. R. Swindell et al., “Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms,” Journal of Investigative Dermatology, vol. 134, no. 7, pp. 1828–1838, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Menter, A. Gottlieb, S. R. Feldman et al., “Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics,” Journal of the American Academy of Dermatology, vol. 58, no. 5, pp. 826–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Psoriasis Study Group svdboCMA, “Guideline for the treatment of psoriasis (2008),” Chinese Journal of Dermatology, vol. 3, pp. 213–214, 2008. View at Google Scholar
  16. A. J. Silman and J. E. Pearson, “Epidemiology and genetics of rheumatoid arthritis,” Arthritis Research & Therapy, vol. 4, supplement 3, pp. S265–S272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Niu, C. Lu, C. Xiao et al., “The shared crosstalk of multiple pathways involved in the inflammation between rheumatoid arthritis and coronary artery disease based on a digital gene expression profile,” PLoS ONE, vol. 9, no. 12, Article ID e113659, 2014. View at Publisher · View at Google Scholar
  18. A. S. Morrissy, R. D. Morin, A. Delaney et al., “Next-generation tag sequencing for cancer gene expression profiling,” Genome Research, vol. 19, no. 10, pp. 1825–1835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. W. R. Swindell, M. K. Sarkar, Y. Liang, X. Xing, and J. E. Gudjonsson, “Cross-disease transcriptomics: unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature,” Journal of Investigative Dermatology, vol. 136, no. 9, pp. 1820–1830, 2016. View at Publisher · View at Google Scholar
  20. X. Niu, C. Lu, C. Xiao et al., “The crosstalk of pathways involved in immune response maybe the shared molecular basis of rheumatoid arthritis and type 2 diabetes,” PLoS ONE, vol. 10, no. 8, Article ID e0134990, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. N. S. Merle, R. Noe, L. Halbwachs-Mecarelli, V. Fremeaux-Bacchi, and L. T. Roumenina, “Complement system part II: role in immunity,” Frontiers in Immunology, vol. 6, article 257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Ballanti, C. Perricone, G. Di Muzio et al., “Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors,” Autoimmunity Reviews, vol. 10, no. 10, pp. 617–623, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Rodríguez-Fernández, “Antigen presentation by dendritic cells in rheumatoid arthritis,” Current Topics in Medicinal Chemistry, vol. 13, no. 6, pp. 712–719, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. E. G. Spack, “Treatment of autoimmune diseases through manipulation of antigen presentation,” Critical Reviews in Immunology, vol. 17, no. 5-6, pp. 529–536, 1997. View at Google Scholar · View at Scopus
  25. A. von Delwig, C. M. U. Hilkens, D. M. Altmann et al., “Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice,” Arthritis Research and Therapy, vol. 8, no. 4, article no. R93, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. W. A. Maltese and J. H. Overmeyer, “Non-apoptotic cell death associated with perturbations of macropinocytosis,” Frontiers in Physiology, vol. 6, article no. 38, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Cray, J. Zaias, and N. H. Altman, “Acute phase response in animals: a review,” Comparative Medicine, vol. 59, no. 6, pp. 517–526, 2009. View at Google Scholar · View at Scopus
  28. N. S. Merle, S. E. Church, V. Fremeaux-Bacchi, and L. T. Roumenina, “Complement system part I—molecular mechanisms of activation and regulation,” Frontiers in Immunology, vol. 6, article no. 262, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Feldmann, “Molecular mechanisms involved in human autoimmune diseases: relevance of chronic antigen presentation. Class II expression and cytokine production,” Immunology, vol. 2, pp. 66–71, 1989. View at Google Scholar · View at Scopus
  30. D. R. Michael, T. G. Ashlin, C. S. Davies et al., “Differential regulation of macropinocytosis in macrophages by cytokines: implications for foam cell formation and atherosclerosis,” Cytokine, vol. 64, no. 1, pp. 357–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Martín, F. Santolaria, N. Batista et al., “Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer,” Cytokine, vol. 11, no. 1, pp. 80–86, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. W. A. Goodman, A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, and K. D. Cooper, “IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells,” Journal of Immunology, vol. 183, no. 5, pp. 3170–3176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. G. Baraldi, B. Cacciari, A. Guiotto, R. Romagnoli, G. Spalluto, and A. N. Zaid, “Synthesis, cytotoxicity and antitumor activity of some new simplified pyrazole analogs of the antitumor agent CC-1065. Effect of an hydrophobic group on antitumor activity,” Farmaco, vol. 52, no. 12, pp. 711–716, 1997. View at Google Scholar · View at Scopus
  34. P. Ataie-Kachoie, M. H. Pourgholami, and D. L. Morris, “Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer,” Cytokine and Growth Factor Reviews, vol. 24, no. 2, pp. 163–173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Muromoto, T. Hirao, K. Tawa et al., “IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes,” International Immunology, vol. 28, no. 9, pp. 443–452, 2016. View at Publisher · View at Google Scholar
  36. S. Klebow, M. Hahn, A. Nikoalev et al., “IL-6 signaling in myelomonocytic cells is not crucial for the development of IMQ-induced psoriasis,” PLoS ONE, vol. 11, no. 3, Article ID e0151913, 2016. View at Publisher · View at Google Scholar
  37. L. C. Zaba, M. Suárez-Fariñas, J. Fuentes-Duculan et al., “Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes,” Journal of Allergy and Clinical Immunology, vol. 124, no. 5, pp. 1022–1030.e395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. Luo, Y. Sun, W. Liu et al., “A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide,” Journal of Immunology, vol. 191, no. 10, pp. 4969–4978, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Zhao, S. N. Grimes, S. Li, X. Hu, and L. B. Ivashkiv, “TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J,” Journal of Experimental Medicine, vol. 209, no. 2, pp. 319–334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Popadic, E. Savic, M. Markovic et al., “TNF, IL12B, and IFNG gene polymorphisms in serbian patients with psoriasis,” Annals of Dermatology, vol. 27, no. 2, pp. 128–132, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Dong, H.-D. Chang, C. Ivascu et al., “Loss of methylation at the IFNG promoter and CNS-1 is associated with the development of functional IFN-γ memory in human CD4+ T lymphocytes,” European Journal of Immunology, vol. 43, no. 3, pp. 793–804, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Li, J. Wang, X. Wang et al., “Increased βTrCP are associated with imiquimod-induced psoriasis-like skin inflammation in mice via NF-κB signaling pathway,” Gene, vol. 592, no. 1, pp. 164–171, 2016. View at Publisher · View at Google Scholar
  43. L. A. Criswell, “Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis,” Immunological Reviews, vol. 233, no. 1, pp. 55–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Zenz, R. Eferl, C. Scheinecker et al., “Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease,” Arthritis Research and Therapy, vol. 10, no. 1, article 201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Durchdewald, P. Angel, and J. Hess, “The transcription factor Fos: a Janus-type regulator in health and disease,” Histology and Histopathology, vol. 24, no. 11, pp. 1451–1461, 2009. View at Google Scholar · View at Scopus
  46. A. Mavropoulos, E. I. Rigopoulou, C. Liaskos, D. P. Bogdanos, and L. I. Sakkas, “The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis,” Clinical and Developmental Immunology, vol. 2013, Article ID 569751, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Johansen, K. Kragballe, M. Westergaard, J. Henningsen, K. Kristiansen, and L. Iversen, “The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin,” British Journal of Dermatology, vol. 152, no. 1, pp. 37–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Hong, C. Shen, H. Ding et al., “An involvement of SR-B1 mediated p38 MAPK signaling pathway in serum amyloid A-induced angiogenesis in rheumatoid arthritis,” Molecular Immunology, vol. 66, no. 2, pp. 340–345, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Tsubaki, T. Takeda, T. Kino et al., “Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2,” American Journal of Translational Research, vol. 7, no. 8, pp. 1371–1381, 2015. View at Google Scholar · View at Scopus